1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016;66:271-89.
[CROSSREF] [PUBMED]
2. Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2018 [Internet]. Bethesda: National Cancer Institute; 2021 [cited 2022 Aug 9]. Available from:
https://seer.cancer.gov/csr/1975_2018/.
3. Jung KW, Won YJ, Kong HJ, Lee ES. Prediction of cancer incidence and mortality in Korea, 2019. Cancer Res Treat 2019;51:431-7.
[CROSSREF] [PUBMED] [PMC] [PDF]
4. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133.
[CROSSREF] [PUBMED] [PMC]
5. Nickel B, Tan T, Cvejic E, Baade P, McLeod DS, Pandeya N, et al. Health-related quality of life after diagnosis and treatment of differentiated thyroid cancer and association with type of surgical treatment. JAMA Otolaryngol Head Neck Surg 2019;145:231-8.
[CROSSREF] [PUBMED] [PMC]
6. Park J, Blackburn BE, Ganz PA, Rowe K, Snyder J, Wan Y, et al. Risk factors for cardiovascular disease among thyroid cancer survivors: findings from the Utah Cancer Survivors Study. J Clin Endocrinol Metab 2018;103:2468-77.
[CROSSREF] [PUBMED] [PMC] [PDF]
7. Blackburn BE, Ganz PA, Rowe K, Snyder J, Wan Y, Deshmukh V, et al. Aging-related disease risks among young thyroid cancer survivors. Cancer Epidemiol Biomarkers Prev 2017;26:1695-704.
[CROSSREF] [PUBMED] [PMC] [PDF]
8. Yin DT, He H, Yu K, Xie J, Lei M, Ma R, et al. The association between thyroid cancer and insulin resistance, metabolic syndrome and its components: a systematic review and meta-analysis. Int J Surg 2018;57:66-75.
[CROSSREF] [PUBMED]
9. Schultz PN, Stava C, Vassilopoulou-Sellin R. Health profiles and quality of life of 518 survivors of thyroid cancer. Head Neck 2003;25:349-56.
[CROSSREF] [PUBMED]
10. Crevenna R, Zettinig G, Keilani M, Posch M, Schmidinger M, Pirich C, et al. Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy. Support Care Cancer 2003;11:597-603.
[CROSSREF] [PUBMED] [PDF]
11. Giusti M, Sibilla F, Cappi C, Dellepiane M, Tombesi F, Ceresola E, et al. A case-controlled study on the quality of life in a cohort of patients with history of differentiated thyroid carcinoma. J Endocrinol Invest 2005;28:599-608.
[CROSSREF] [PUBMED] [PDF]
12. Tagay S, Herpertz S, Langkafel M, Erim Y, Bockisch A, Senf W, et al. Health-related quality of life, depression and anxiety in thyroid cancer patients. Qual Life Res 2006;15:695-703.
[CROSSREF] [PUBMED] [PDF]
13. Tan LG, Nan L, Thumboo J, Sundram F, Tan LK. Health-related quality of life in thyroid cancer survivors. Laryngoscope 2007;117:507-10.
[CROSSREF] [PUBMED]
14. Hoftijzer HC, Heemstra KA, Corssmit EP, van der Klaauw AA, Romijn JA, Smit JW. Quality of life in cured patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008;93:200-3.
[CROSSREF] [PUBMED] [PDF]
15. Maki Y, Horiuchi K, Okamoto T. Fatigue and quality of life among thyroid cancer survivors without persistent or recurrent disease. Endocr Connect 2022;11:e210506.
[CROSSREF] [PUBMED] [PMC]
16. Pitoia F, Jerkovich F. Dynamic risk assessment in patients with differentiated thyroid cancer. Endocr Relat Cancer 2019;26:R553-66.
[CROSSREF] [PUBMED]
17. Yi KH. The revised 2016 Korean Thyroid Association guidelines for thyroid nodules and cancers: differences from the 2015 American Thyroid Association guidelines. Endocrinol Metab (Seoul) 2016;31:373-8.
[CROSSREF] [PUBMED] [PMC] [PDF]
18. Kim MH, Cho YS, Uhm WS, Kim S, Bae SC. Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases. Qual Life Res 2005;14:1401-6.
[CROSSREF] [PUBMED] [PDF]
19. Mozzi A, Meregaglia M, Lazzaro C, Tornatore V, Belfiglio M, Fattore G. A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample. Clinicoecon Outcomes Res 2016;8:267-74.
[CROSSREF] [PUBMED] [PMC]
20. Lee YK, Nam HS, Chuang LH, Kim KY, Yang HK, Kwon IS, et al. South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. Value Health 2009;12:1187-93.
[CROSSREF] [PUBMED]
21. Gao YJ, Li B, Wu XY, Cui J, Han JK. Thyroid tumor-initiating cells: increasing evidence and opportunities for anticancer therapy (review). Oncol Rep 2014;31:1035-42.
[CROSSREF] [PUBMED] [PMC]
22. Megwalu UC, Moon PK. Thyroid cancer incidence and mortality trends in the United States: 2000-2018. Thyroid 2022;32:560-70.
[CROSSREF] [PUBMED]
23. Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016;130(S2):S150-60.
[CROSSREF] [PUBMED] [PMC]
24. Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:1856-83.
[CROSSREF] [PUBMED] [PDF]
25. Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, et al. 2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J 2019;8:227-45.
[CROSSREF] [PUBMED] [PMC] [PDF]
26. Goswami S, Peipert BJ, Mongelli MN, Kurumety SK, Helenowski IB, Yount SE, et al. Clinical factors associated with worse quality-of-life scores in United States thyroid cancer survivors. Surgery 2019;166:69-74.
[CROSSREF] [PUBMED]
27. Kurumety SK, Helenowski IB, Goswami S, Peipert BJ, Yount SE, Sturgeon C. Post-thyroidectomy neck appearance and impact on quality of life in thyroid cancer survivors. Surgery 2019;165:1217-21.
[CROSSREF] [PUBMED]
28. Bongers PJ, Greenberg CA, Hsiao R, Vermeer M, Vriens MR, Lutke Holzik MF, et al. Differences in long-term quality of life between hemithyroidectomy and total thyroidectomy in patients treated for low-risk differentiated thyroid carcinoma. Surgery 2020;167:94-101.
[CROSSREF] [PUBMED]
29. Lee S, Kim HY, Lee CR, Park S, Son H, Kang SW, et al. A prospective comparison of patient body image after robotic thyroidectomy and conventional open thyroidectomy in patients with papillary thyroid carcinoma. Surgery 2014;156:117-25.
[CROSSREF] [PUBMED]
30. Lee JA, Kim SY, Kim Y, Oh J, Kim HJ, Jo DY, et al. Comparison of health-related quality of life between cancer survivors treated in designated cancer centers and the general public in Korea. Jpn J Clin Oncol 2014;44:141-52.
[CROSSREF] [PUBMED]
31. Dingle IF, Mishoe AE, Nguyen SA, Overton LJ, Gillespie MB. Salivary morbidity and quality of life following radioactive iodine for well-differentiated thyroid cancer. Otolaryngol Head Neck Surg 2013;148:746-52.
[CROSSREF] [PUBMED] [PDF]
32. Barbus E, Pestean C, Larg MI, Gabora K, Bonci EA, Badulescu C, et al. Psychological impact of 131I radioprotection measures on thyroid cancer patients. Clujul Med 2018;91:441-7.
[CROSSREF] [PUBMED] [PMC] [PDF]
33. Shakir MK, Krook LS, Schraml FV, Hays JH, Clyde PW. Symptomatic hyponatremia in association with a low-iodine diet and levothyroxine withdrawal prior to I131 in patients with metastatic thyroid carcinoma. Thyroid 2008;18:787-92.
[CROSSREF] [PUBMED]
34. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878-84.
[CROSSREF] [PUBMED] [PDF]
35. Borget I, Bonastre J, Catargi B, Deandreis D, Zerdoud S, Rusu D, et al. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the Randomized Phase III ESTIMABL Trial. J Clin Oncol 2015;33:2885-92.
[CROSSREF] [PUBMED]
36. Eustatia-Rutten CF, Corssmit EP, Pereira AM, Frolich M, Bax JJ, Romijn JA, et al. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clin Endocrinol (Oxf) 2006;64:284-91.
[CROSSREF] [PUBMED]
37. Valle LA, Gorodeski Baskin RL, Porter K, Sipos JA, Khawaja R, Ringel MD, et al. In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin. Thyroid 2013;23:185-93.
[CROSSREF] [PUBMED] [PMC]
38. Massolt ET, van der Windt M, Korevaar TI, Kam BL, Burger JW, Franssen GJ, et al. Thyroid hormone and its metabolites in relation to quality of life in patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf) 2016;85:781-8.
[CROSSREF] [PUBMED]
39. Jung MS, Visovatti M. Post-treatment cognitive dysfunction in women treated with thyroidectomy for papillary thyroid carcinoma. Support Care Cancer 2017;25:915-23.
[CROSSREF] [PUBMED] [PDF]
40. Lee JC, Song BS, Kang YM, Kim YR, Kang YE, Lee JH, et al. Effect of thyroid-stimulating hormone suppression on muscle function after total thyroidectomy in patients with thyroid cancer. Front Endocrinol (Lausanne) 2021;12:769074.
[CROSSREF] [PUBMED] [PMC]
41. Pickard AS, Wilke CT, Lin HW, Lloyd A. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 2007;25:365-84.
[CROSSREF] [PUBMED]
42. Husson O, Haak HR, Mols F, Nieuwenhuijzen GA, Nieuwlaat WA, Reemst PH, et al. Development of a disease-specific health-related quality of life questionnaire (THYCA-QoL) for thyroid cancer survivors. Acta Oncol 2013;52:447-54.
[CROSSREF] [PUBMED]
43. Watt T, Hegedus L, Groenvold M, Bjorner JB, Rasmussen AK, Bonnema SJ, et al. Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur J Endocrinol 2010;162:161-7.
[CROSSREF] [PUBMED]
44. Bernardo DC, Li RJ, Jimeno C. Validity and reliability of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30: tagalog among adult filipinos with differentiated thyroid cancer. J ASEAN Fed Endocr Soc 2018;33:174-80.
[CROSSREF] [PUBMED] [PMC]
45. Lee JI, Kim SH, Tan AH, Kim HK, Jang HW, Hur KY, et al. Decreased health-related quality of life in disease-free survivors of differentiated thyroid cancer in Korea. Health Qual Life Outcomes 2010;8:101.
[CROSSREF] [PUBMED] [PMC] [PDF]
46. Singer S, Lincke T, Gamper E, Bhaskaran K, Schreiber S, Hinz A, et al. Quality of life in patients with thyroid cancer compared with the general population. Thyroid 2012;22:117-24.
[CROSSREF] [PUBMED]
47. McIntyre C, Jacques T, Palazzo F, Farnell K, Tolley N. Quality of life in differentiated thyroid cancer. Int J Surg 2018;50:133-6.
[CROSSREF] [PUBMED]
48. Wang T, Jiang M, Ren Y, Liu Q, Zhao G, Cao C, et al. Health-related quality of life of community thyroid cancer survivors in Hangzhou, China. Thyroid 2018;28:1013-23.
[CROSSREF] [PUBMED]
49. Hirsch D, Ginat M, Levy S, Benbassat C, Weinstein R, Tsvetov G, et al. Illness perception in patients with differentiated epithelial cell thyroid cancer. Thyroid 2009;19:459-65.
[CROSSREF] [PUBMED]
50. Huang SM, Lee CH, Chien LY, Liu HE, Tai CJ. Postoperative quality of life among patients with thyroid cancer. J Adv Nurs 2004;47:492-9.
[CROSSREF] [PUBMED]